Abvc biopharma announces principal investigator meeting for phase ii part 2 adhd clinical study

Fremont, ca, feb. 02, 2022 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that the principal investigator meeting for the abv-1505 phase ii part 2 adhd clinical study will be held on february 14, 2022. principal investigators from the university of california san francisco (“ucsf”) medical center and five prestigious taiwan medical centers, including national taiwan university hospital, taipei veterans general hospital, linkou chang gung memorial hospital, kaohsiung chang gung memorial hospital and cheng hsin general hospital, will virtually participate in the meeting to discuss potential further improvement to the study protocol prior to initiation.
ABVC Ratings Summary
ABVC Quant Ranking